| Schedule of Segment Reporting Information |
Segment
information for the year ended December 31, 2025 is presented below:
Schedule
of Segment Reporting Information
| | |
Pharmaceutical Operations | | |
Premium Nutritional Supplements | | |
Total
Reportable Segments | | |
Corporate
/ Other | | |
Consolidated
Total | |
| Revenue | |
| - | | |
| 21,796 | | |
| 21,796 | | |
| - | | |
| 21,796 | |
| Cost
of goods sold | |
| - | | |
| 4,231 | | |
| 4,231 | | |
| - | | |
| 4,231 | |
| Research
and development | |
| 2,086,574 | | |
| - | | |
| 2,086,574 | | |
| - | | |
| 2,086,574 | |
| Selling,
general and administrative | |
| 817,554 | | |
| 1,179,492 | | |
| 1,997,046 | | |
| 4,842,666 | | |
| 6,839,712 | |
| Segment
net loss | |
| (2,904,128 | ) | |
| (1,161,927 | ) | |
| (4,066,055 | ) | |
| (4,842,666 | ) | |
| (8,908,721 | ) |
| Other interest
income (expense), net | |
| - | | |
| - | | |
| - | | |
| 263,824 | | |
| 263,824 | |
| Net
loss | |
| (2,904,128 | ) | |
| (1,161,927 | ) | |
| (4,066,055 | ) | |
| (4,578,842 | ) | |
| (8,644,897 | ) |
|